Get the Stockscreener App
34.91
0.27%
0.075
Genmab Adr stock is traded at $34.91, with a volume of 1.79M.
It is up +0.27% in the last 24 hours and up +1.64% over the past month.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$34.83
Open:
$34.95
24h Volume:
1.79M
Relative Volume:
0.80
Market Cap:
$21.46B
Revenue:
$3.91B
Net Income/Loss:
$823.88M
P/E Ratio:
26.32
EPS:
1.3262
Net Cash Flow:
$875.28M
1W Performance:
+0.53%
1M Performance:
+1.64%
6M Performance:
+33.76%
1Y Performance:
+21.10%
1-Day Range:
$34.70
$35.14
1-Week Range:
$33.22
$35.66
52-Week Range:
$23.62
$35.66
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
34.91 | 21.42B | 3.91B | 823.88M | 875.28M | 1.3262 |
VRTX
Vertex Pharmaceuticals Inc
|
520.59 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
786.95 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
197.51 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
961.17 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
209.76 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Upgrade | Goldman | Neutral → Buy |
| Mar-27-26 | Initiated | Wolfe Research | Outperform |
| Mar-02-26 | Initiated | Wells Fargo | Overweight |
| Feb-17-26 | Resumed | Jefferies | Buy |
| Feb-17-26 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-23-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-01-25 | Downgrade | Bernstein | Mkt Perform → Underperform |
| Mar-11-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-13-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-20-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-15-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-23-24 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Dec-06-23 | Upgrade | UBS | Neutral → Buy |
| Nov-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-08-23 | Upgrade | DNB Markets | Sell → Buy |
| Oct-18-23 | Initiated | Exane BNP Paribas | Underperform |
| Sep-06-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-24-23 | Initiated | BTIG Research | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-31-23 | Initiated | UBS | Neutral |
| May-12-23 | Initiated | Morgan Stanley | Underweight |
| Dec-20-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-14-22 | Initiated | William Blair | Mkt Perform |
| Nov-11-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-24-22 | Initiated | BMO Capital Markets | Market Perform |
| May-02-22 | Initiated | Cowen | Market Perform |
| Mar-16-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-01-21 | Initiated | Berenberg | Sell |
| Sep-16-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-24-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Jan-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-20 | Downgrade | Bryan Garnier | Neutral → Sell |
| Sep-08-20 | Initiated | SVB Leerink | Mkt Perform |
| Jun-25-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-23-20 | Initiated | Credit Suisse | Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Sep-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | Morgan Stanley | Overweight |
| Aug-12-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Genmab Adr Stock (GMAB) Latest News
Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewswire Inc.
Genmab stock heads into the open after a 0.84 percent gain - AD HOC NEWS
Genmab stock gains as Kempen raises target to DKK 3,300 - AD HOC NEWS
Genmab stock holds steady after first-half 2026 earnings update - AD HOC NEWS
Genmab stock gains as petosemtamab and Q2 figures draw focus - AD HOC NEWS
Genmab stock gains as petosemtamab Phase 3 start and strong Q2 figures support valuation - AD HOC NEWS
Genmab stock gains as HC Wainwright lifts Q3 earnings estimates and Phase 3 petosemtamab trial begin - AD HOC NEWS
Weekly Recap: Epcoritamab Phase III readout and DKK 44.3m share issuance - TradingView
symbol__ Stock Quote Price and Forecast - CNN
ETFs Investing in Genmab A/S Sponsored ADR Stocks - TradingView
Genmab stock holds steady as analysts stick to a moderate buy view - AD HOC NEWS
Genmab A/S ADSADR Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Genmab stock holds in the mid-$30s as higher 2026 guidance leans on royalty income - ad-hoc-news.de
Genmab stock steadies as 2026 royalty-driven guidance lifts revenue outlook - AD HOC NEWS
Genmab stock holds steady as 2026 royalty-driven guidance is raised - ad-hoc-news.de
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI) - The Globe and Mail
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Legacy Wealth Asset Management LLC Grows Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Q2 Earnings Call Highlights - Yahoo Finance
Quantinno Capital Management LP Grows Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab (GMAB) Posts Perfect Technical and Setup Scores in Breakout Setup - ChartMill
SummitTX Capital L.P. Makes New Investment in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Bought by Renaissance Technologies LLC - MarketBeat
Genmab/AbbVie lymphoma trial meets main goal, analyst eyes bigger market opportunity - MSN
Barometer Capital Management Inc. Boosts Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? - MSN
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Diversify Wealth Management LLC Takes $1.22 Million Position in Genmab A/S Sponsored ADR $GMAB - marketbeat.com
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
GMABGenmab ADR Earnings - Finviz
Amazon To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Genmab (GMAB) Shows Modest Gains Amid Consolidation: Support and Resistance Levels in FocusFair Value Gap - dars.gov.et
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - Sahm
Genmab opens the weekend with a clear strategy focus, shares hold their biotech range - Ad-hoc-news.de
Genmab A/S Sponsored ADR Actuals & Estimates (NASDAQ:GMAB) - TradingView
GE91 Forecast — Price Target — Prediction for 2027 - TradingView
GMAB1/N Forecast — Price Target — Prediction for 2027 - TradingView
GMAB News | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab A/S stock (DK0010272202): Copenhagen shares weaken as investors weigh outlook after updated A - AD HOC NEWS
GMAB Q1 2026 Earnings: EPS Misses Estimates by Over 40% as Stock DeclinesQuarterly Earnings Report - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
GMAB Stock Price, Quote & Chart | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
GMAB vs. ACAD: Which Stock Is the Better Value Option? - MSN
Genmab A/S stock (DK0010272202): earnings momentum and oncology pipeline keep investors watching - AD HOC NEWS
Genmab stock (DK0010272202): Analyst sentiment shifts as earnings forecasts decline - AD HOC NEWS
Genmab Earnings: Strong Patient Uptake and Diverse Late-Stage Pipeline Support Positive Outlook - Morningstar
Genmab A/S Q1 Earnings Call Highlights - Yahoo Finance
Oppenheimer Asset Management Inc. Acquires 48,894 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Pictet Asset Management Holding SA Takes $33.84 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR shows improved relative strength; still shy of benchmark - MSN
Genmab Adr Stock (GMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genmab Adr Stock (GMAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
2,978 |
288,866 |
72,831,487 |
| GENMAB A/S | 10% Owner |
Dec 23 '25 |
Buy |
97.00 |
561,042 |
54,421,074 |
72,589,817 |
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
142,610 |
13,833,170 |
72,828,509 |
| GENMAB A/S | 10% Owner |
Dec 24 '25 |
Buy |
97.00 |
96,082 |
9,319,954 |
72,685,899 |
| GENMAB A/S | 10% Owner |
Dec 22 '25 |
Buy |
97.00 |
15,710 |
1,523,870 |
72,028,775 |
| GENMAB A/S | 10% Owner |
Dec 18 '25 |
Buy |
97.00 |
212,177 |
20,581,169 |
71,946,801 |
| GENMAB A/S | 10% Owner |
Dec 19 '25 |
Buy |
97.00 |
66,264 |
6,427,608 |
72,013,065 |
| GENMAB A/S | 10% Owner |
Dec 17 '25 |
Buy |
97.00 |
150,795 |
14,627,115 |
71,734,624 |
| GENMAB A/S | 10% Owner |
Dec 16 '25 |
Buy |
97.00 |
120,752 |
11,712,944 |
71,583,829 |
4.12%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):